Skip to main content
. 2022 May 6;6(9):2884–2892. doi: 10.1182/bloodadvances.2021006623

Table 1.

Baseline characteristics of the 107 participants

Users of tamoxifen (n=42) Users of aromatase inhibitors (n=65)
Age, y 49.5 (8.9) 65.5 (9.4)
Weight, kg 65.7 (11.0) 69.8 (13.9)
BMI, kg/m2 24.7 (4.5) 26.4 (4.9)
Parity 1.7 (0.9) 1.7 (1.2)
Nonmenopausal status 31 (73.8%) 0 (0%)
Previous hysterectomy 1 (2.4%) 11 (16.9%)
Diabetes 1 (2.4%) 7 (10.9%)
Hypertension 2 (4.8%) 26 (40%)
Dyslipidemia 4 (9.5%) 19 (29.2%)
Current smoking 8 (19.1%) 10 (15.4%)
Previous coronary heart disease 0 (0%) 3 (4.6%)
Previous cerebrovascular disease 0 (0%) 2 (3.1%)
Breast cancer stage
 0 7 (16.7%) 2 (3.1%)
 IA 22 (52.4%) 33 (50.8%)
 IB 2 (4.8%) 4 (6.2%)
 IIA 5 (11.9%) 16 (24.6%)
 IIB 3 (7.1%) 8 (12.3%)
 IIIA 2 (4.5%) 1 (1.5%)
 IIIB 0 (0%) 1 (1.5%)
 IIIC 1 (2.4%) 0 (0%)
Previous cancer treatment
 Breast surgery 42 (100%) 64 (98.5%)
 Time from surgery to inclusion, days 107 (64) 104 (73)
 Breast radiotherapy before inclusion 33 (78.6%) 57 (87.7%)

Numbers are mean (standard deviation) or n (%).